Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAntonic, Ana-
dc.contributor.authorDottori, Mirella-
dc.contributor.authorMacleod, Malcolm R-
dc.contributor.authorDonnan, Geoffrey A-
dc.contributor.authorHowells, David W-
dc.identifier.citationJournal of stroke and cerebrovascular diseases 2018; 27(8): 2158-2165-
dc.description.abstractDeveloping new medicines is a complex process where understanding the reasons for both failure and success takes us forward. One gap in our understanding of most candidate stroke drugs before clinical trial is whether they have a protective effect on human tissues. NXY-059 is a spin-trap reagent hypothesized to have activity against the damaging oxidative biology which accompanies ischemic stroke. Re-examination of the preclinical in vivo dataset for this agent in the wake of the failed SAINT-II RCT highlighted the presence of a range of biases leading to overestimation of the magnitude of NXY-059's effects in laboratory animals. Therefore, NXY-059 seemed an ideal candidate to evaluate in human neural tissues to determine whether human tissue testing might improve screening efficiency. The aim of this randomized and blinded study was to assess the effects of NXY-059 on human stem cell-derived neurons in the presence of ischemia-like injury induced by oxygen glucose deprivation or oxidative stress induced by hydrogen peroxide or sodium nitroprusside. In MTT assays of cell survival, lactate dehydrogenase assays of total cell death and terminal deoxynucleotidyl transferase dUTP nick end labeling staining of apoptotic-like cell death, NXY-059 at concentrations ranging from 1 µm to 1 mm was completely without activity. Conversely an antioxidant cocktail comprising 100 µm each of ascorbate, reduced glutathione, and dithiothreitol used as a positive control provided marked neuronal protection in these assays. These findings support our hypothesis that stroke drug screening in human neural tissues will be of value and provides an explanation for the failure of NXY-059 as a human stroke drug.-
dc.subjectIschaemic Stroke-
dc.subjectstem cells-
dc.titleNXY-059, a Failed Stroke Neuroprotectant, Offers No Protection to Stem Cell-Derived Human Neurons.-
dc.typeJournal Article-
dc.identifier.journaltitleJournal of stroke and cerebrovascular diseases : the official journal of National Stroke Association-
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Neuroscience, Central Clinical School, Monash University, The Alfred Centre, Victoria, Australia-
dc.identifier.affiliationIllawarra Health and Medical Research Institute, Centre for Molecular and Medical Bioscience, University of Wollongong, Wollongong, New South Wales, Australia-
dc.identifier.affiliationDepartment of Clinical Neurosciences, University of Edinburgh, Edinburgh, UK-
dc.identifier.affiliationUniversity of Tasmania, School of Medicine, Faculty of Health, Hobart, Tasmania, Australia-
dc.type.austinJournal Article-
item.fulltextNo Fulltext-
item.openairetypeJournal Article- Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Feb 5, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.